Cantor Fitzgerald Reiterates Johnson & Johnson (JNJ) at Overweight, Pharm Business is Underappreciated, Expect Upwards Earnings Revisions and Multiple Expansion
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $215.00 price target on Johnson & Johnson (NYSE: JNJ), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
